112例老年晚期非小细胞肺癌病人一线应用EGFR-TKIs的疗效及安全性观察

Efficacy and safety of EGFR-TKIs as first-line treatment in 112 elder patients with advanced non-small cell lung cancer

关键词:  晚期非小细胞肺癌  吉非替尼  厄洛替尼  埃可替尼  老年

Key words:  [Key words]　advanced non-small cell lung cancer  gefitinib  erlotinib  icotinib  elder patients

摘要:

[摘要]　目的　观察在晚期老年非小细胞肺癌患者中一线应用EGFR-TKIs靶向治疗药物的疗效及安全性。　方法　选取70岁以上晚期非小细胞肺癌患者共112例，应用吉非替尼（250 mg 1次/d口服）68例，应用厄洛替尼（150 mg 1次/d口服）15例，应用埃可替尼（125 mg 3次/d口服）29例。 观察患者接受EGFR-TKIs治疗的疗效、不良反应及无进展生存期(PFS)。　结果　112例患者接受EGFR-TKIs治疗，共 109例完成治疗，本组无CR病例，26例患者获得PR，42例患者疗效为SD，41例患者PD，有效率（ORR）23.8%，疾病控制率（DCR）62.4%。3例不能耐受而中止用药。全组患者中位无进展生存期(mPFS)为6.0个月。吉非替尼、厄洛替尼、埃可替尼各组间疗效无明显差异，P>0.05。 　结论　晚期老年非小细胞肺癌患者应用EGFR-TKIs靶向治疗药物安全有效，不良反应轻微，可耐受。吉非替尼、厄洛替尼、埃可替尼疗效无明显差异。

Abstract:

[Abstract]　Objective　To study the efficacy and safety of EGFR-TKIs as the first-line therapy in elder patients with advanced non-small cell lung cancer.　Methods　112 cases of advanced non-small cell lung cancer in patients aged beyond 70 years were analyzed, including 68 treated with Gefitinib (250 mg, qd), 15 with Erlotinib (150 mg, qd), and 29 with Icotinib (125 mg, tid). To study the efficacy and median progression-free survival of EGFR-TKIs therapy.　Results　Of the 112 patients who received EGFR-TKI treatment, 109 patients finished the course. No CR was observed. PR, SD and PD were found in 26, 42 and 41 patients, respectively with ORR 23.8% and DCR 62.4%. 3 patients discontinued the medication because of intolerance. mPFS was 6.0 months.　Conclusions　EGFR-TKIs is a safe and effective targeted therapy in old patients with advanced non-small cell lung cancer. No difference in efficacy can be concluded in the comparison among Gefitinib, Icotinib and Erlotinib.